Ra Pharmaceuticals Inc (NASDAQ:RARX)‘s stock had its “buy” rating reissued by equities research analysts at Jefferies Group in a note issued to investors on Wednesday.

The analysts wrote, “Roughly in-line 3Q16 net loss of $8.1M; our estimated cash of $116M at end- FY16 should be at least sufficient into 2H18 based on our forecast. Key catalyst is Ph2 data for lead product RA101495 in PNH pts in 2H17; if positive (similar to Soliris), we view >100% potential upside as likely from current levels.””

Other analysts also recently issued research reports about the company. SunTrust Banks Inc. assumed coverage on Ra Pharmaceuticals in a research note on Monday, November 21st. They issued a “buy” rating and a $32.00 price target on the stock. Credit Suisse Group AG assumed coverage on Ra Pharmaceuticals in a research note on Monday, November 21st. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, BMO Capital Markets assumed coverage on Ra Pharmaceuticals in a research note on Monday, November 21st. They set an “outperform” rating and a $26.00 target price on the stock.

Shares of Ra Pharmaceuticals (NASDAQ:RARX) traded up 0.3346% during mid-day trading on Wednesday, hitting $13.0435. The company’s stock had a trading volume of 11,800 shares. The company’s market cap is $7.23 million. The stock’s 50 day moving average price is $13.16 and its 200 day moving average price is $13.16. Ra Pharmaceuticals has a 52-week low of $12.33 and a 52-week high of $14.86.

ILLEGAL ACTIVITY WARNING: This report was posted by Daily Political and is the propert of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of US and international copyright & trademark law. The original version of this report can be accessed at http://www.dailypolitical.com/2016/11/30/ra-pharmaceuticals-inc-rarx-rating-reiterated-by-jefferies-group.html.

In other Ra Pharmaceuticals news, Director Rajeev M. Shah bought 161,538 shares of the business’s stock in a transaction on Monday, October 31st. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $2,099,994.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Harry R. Weller bought 338,462 shares of the business’s stock in a transaction on Monday, October 31st. The shares were acquired at an average price of $13.00 per share, for a total transaction of $4,400,006.00. The disclosure for this purchase can be found here.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

5 Day Chart for NASDAQ:RARX

Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.